Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Hold" from Analysts

Key Points

• Analyst sentiment is mixed: Personalis has an average “Hold” rating from nine analysts, with four buys, three holds and two sells. The average 12-month price target is $14.25.
• Insiders have been selling shares: Executives sold 435,032 shares worth approximately $5.6 million over the past 90 days, while insiders retain a 4.2% ownership stake.
• Recent results were mixed: Personalis reported quarterly revenue of $22.36 million, beating estimates of $16.69 million, but its $0.30 loss per share was wider than the expected $0.26 loss.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has earned an average recommendation of "Hold" from the nine analysts that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $14.25.

Several research firms have recently weighed in on PSNL. BTIG Research upped their price target on shares of Personalis from $11.00 to $16.25 and gave the stock a "buy" rating in a report on Monday, July 20th. Lake Street Capital lowered Personalis from a "buy" rating to a "hold" rating and set a $16.25 price objective for the company. in a research note on Monday, July 20th. Wall Street Zen cut Personalis from a "hold" rating to a "sell" rating in a research report on Saturday, June 13th. TD Cowen restated a "buy" rating on shares of Personalis in a research note on Wednesday, July 15th. Finally, Needham & Company LLC cut shares of Personalis from a "buy" rating to a "hold" rating in a research report on Monday, July 20th.

Insider Buying and Selling

In related news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer owned 235,986 shares of the company's stock, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction on Monday, June 29th. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the transaction, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,783,662. The trade was a 2.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 435,032 shares of company stock valued at $5,599,929. Company insiders own 4.20% of the company's stock.

Hedge Funds Weigh In On Personalis

Hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock valued at $27,000 after buying an additional 1,479 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Personalis during the fourth quarter valued at approximately $31,000. Legal & General Group Plc bought a new position in shares of Personalis during the second quarter valued at $30,000. BNP Paribas Financial Markets lifted its stake in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock valued at $42,000 after acquiring an additional 5,177 shares during the period. Finally, AQR Capital Management LLC bought a new position in Personalis during the fourth quarter valued at approximately $82,000. Hedge funds and other institutional investors own 61.91% of the company's stock.

Personalis Trading Up 8.7%

PSNL opened at $14.16 on Friday. The company has a market cap of $1.48 billion, a PE ratio of -12.99 and a beta of 2.27. Personalis has a 12 month low of $4.35 and a 12 month high of $16.39. The company has a 50 day moving average of $12.39 and a 200 day moving average of $9.33.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.04). Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%.The firm had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Research analysts forecast that Personalis will post -1.07 earnings per share for the current fiscal year.

About Personalis

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source